Role:
This is a technical leadership role within Analytical Development and will lead fit for purpose method development and support testing for, but not limited to, in process and product assays for B cell medicine, the expressed protein, and process impurities. They will contribute to process improvements by driving supporting analytical assays and leverage high throughput methods to drive efficiency. They also play a critical role in manufacturing troubleshooting, root cause investigation, and support tech transfer of processes to manufacturing with in-process assay sampling plans. This individual will also act as a technical subject matter expert for various assays routinely used at Be Bio and contribute to expanding the repertoire of assays. You will improve and execute efficient processes and procedures including sample testing, data management, report writing, and documentation for important studies to support the portfolio. This is a great opportunity to develop and mentor a high-performing team of scientists with a vision of setting industry-leading scientific standards in a growing function that will require hands-on work to instruct and build the necessary skills within the group while leading day-to-day group activities including timeline and budget management and objective setting and execution.
Responsibilities:
Experience, Education, Specialized Knowledge, and Skills:
Must thrive in a fast-paced, growing, and innovative environment with changing priorities where flexibility, resourcefulness, resiliency, and communication skills are key. Excellent interpersonal skills, ability to develop important relationships and open communication with your stakeholders, and being an all around good company citizen are essential.
About Be Biopharma
Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute. Be Bio is backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb and Takeda Ventures. Since our founding, Be Bio’s investors have committed over $180 million to enable the Company to re-imagine medicine based on the power of B cell therapy. For more information, please visit us at Be.Bio and our LinkedIn page.
Culture
The beating heart of Be Bio is our People and together we are building a culture driven by purpose, passion, and that’s full of character. We are “all-in” as we align ourselves with patients who need our medicines, and we embrace the highest standards of transparency, excellence, candor, collaboration, and team-based science with a shared ownership of company milestones and successes.
Our commitment to our team members is to deliver a compelling, dynamic work experience that enables them to continually stretch, grow, and learn, that enriches their lives, that fosters a sense of belonging and community, and that goes above and beyond to support them in big, meaningful ways in both their personal and professional lives. Be Bio is a team that works hard, plays hard, and supports each other on our shared journey to get transformative medicines to patients who need them.
